- Home
- VERX vs LEGN Comparison
VERX vs LEGN Comparison
Compare VERX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERX
- LEGN
- Stock Information
- Founded
- VERX 1978
- LEGN 2014
- Country
- VERX United States
- LEGN United States
- Employees
- VERX N/A
- LEGN N/A
- Industry
- VERX Computer Software: Prepackaged Software
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- VERX Technology
- LEGN Health Care
- Exchange
- VERX Nasdaq
- LEGN Nasdaq
- Market Cap
- VERX 5.7B
- LEGN 5.4B
- IPO Year
- VERX 2020
- LEGN 2020
- Fundamental
- Price
- VERX $25.62
- LEGN $37.47
- Analyst Decision
- VERX Buy
- LEGN Strong Buy
- Analyst Count
- VERX 13
- LEGN 10
- Target Price
- VERX $42.83
- LEGN $73.67
- AVG Volume (30 Days)
- VERX 1.7M
- LEGN 1.1M
- Earning Date
- VERX 08-06-2025
- LEGN 08-11-2025
- Dividend Yield
- VERX N/A
- LEGN N/A
- EPS Growth
- VERX N/A
- LEGN N/A
- EPS
- VERX N/A
- LEGN N/A
- Revenue
- VERX $710,512,000.00
- LEGN $796,838,000.00
- Revenue This Year
- VERX $16.79
- LEGN $66.76
- Revenue Next Year
- VERX $14.63
- LEGN $52.58
- P/E Ratio
- VERX N/A
- LEGN N/A
- Revenue Growth
- VERX 15.00
- LEGN 74.75
- 52 Week Low
- VERX $24.45
- LEGN $27.34
- 52 Week High
- VERX $60.71
- LEGN $59.62
- Technical
- Relative Strength Index (RSI)
- VERX 29.24
- LEGN 46.46
- Support Level
- VERX $24.45
- LEGN $36.13
- Resistance Level
- VERX $26.52
- LEGN $37.99
- Average True Range (ATR)
- VERX 1.30
- LEGN 1.36
- MACD
- VERX -0.52
- LEGN -0.43
- Stochastic Oscillator
- VERX 15.12
- LEGN 36.20
About VERX Vertex Inc.
Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. Vertex provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting among others. The company derives revenue from software subscriptions.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.